JP2013519699A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519699A5
JP2013519699A5 JP2012553267A JP2012553267A JP2013519699A5 JP 2013519699 A5 JP2013519699 A5 JP 2013519699A5 JP 2012553267 A JP2012553267 A JP 2012553267A JP 2012553267 A JP2012553267 A JP 2012553267A JP 2013519699 A5 JP2013519699 A5 JP 2013519699A5
Authority
JP
Japan
Prior art keywords
molecule
domain
fviii
another embodiment
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012553267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519699A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/051959 external-priority patent/WO2011101284A1/en
Publication of JP2013519699A publication Critical patent/JP2013519699A/ja
Publication of JP2013519699A5 publication Critical patent/JP2013519699A5/ja
Withdrawn legal-status Critical Current

Links

JP2012553267A 2010-02-16 2011-02-10 因子viii融合タンパク質 Withdrawn JP2013519699A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10153715 2010-02-16
EP10153715.7 2010-02-16
US30617710P 2010-02-19 2010-02-19
US61/306,177 2010-02-19
PCT/EP2011/051959 WO2011101284A1 (en) 2010-02-16 2011-02-10 Factor viii fusion protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016021624A Division JP6185097B2 (ja) 2010-02-16 2016-02-08 因子viii融合タンパク質

Publications (2)

Publication Number Publication Date
JP2013519699A JP2013519699A (ja) 2013-05-30
JP2013519699A5 true JP2013519699A5 (enExample) 2015-07-02

Family

ID=42244627

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012553267A Withdrawn JP2013519699A (ja) 2010-02-16 2011-02-10 因子viii融合タンパク質
JP2016021624A Expired - Fee Related JP6185097B2 (ja) 2010-02-16 2016-02-08 因子viii融合タンパク質
JP2017144266A Withdrawn JP2017190342A (ja) 2010-02-16 2017-07-26 因子viii融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016021624A Expired - Fee Related JP6185097B2 (ja) 2010-02-16 2016-02-08 因子viii融合タンパク質
JP2017144266A Withdrawn JP2017190342A (ja) 2010-02-16 2017-07-26 因子viii融合タンパク質

Country Status (5)

Country Link
US (2) US9493543B2 (enExample)
EP (2) EP2977055A1 (enExample)
JP (3) JP2013519699A (enExample)
CN (2) CN105153313A (enExample)
WO (1) WO2011101284A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
CN102770449B (zh) * 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
CN104271150A (zh) * 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
ES2935489T3 (es) 2012-02-15 2023-03-07 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
JP2015519313A (ja) 2012-04-24 2015-07-09 ノヴォ ノルディスク アー/エス 血友病の治療に適する医薬組成物
NZ703366A (en) 2012-07-11 2018-03-23 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
US9815871B2 (en) 2013-04-23 2017-11-14 President And Fellows Of Harvard College Genetic reprogramming of bacterial biofilms
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. 第viii因子両性イオンポリマーコンジュゲート
PL3091997T3 (pl) 2014-01-10 2023-01-02 Bioverativ Therapeutics Inc. Białka chimeryczne czynnika viii i ich zastosowania
EP3114138B1 (en) * 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3177317B1 (en) 2014-08-04 2020-03-18 CSL Limited Factor viii formulation
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
EP3280397A4 (en) 2015-04-06 2018-08-22 President and Fellows of Harvard College Biosynthetic amyloid-based materials displaying functional protein sequences
WO2016198521A1 (en) * 2015-06-10 2016-12-15 Novo Nordisk A/S Fviii fusion proteins
CN104926946B (zh) * 2015-07-13 2021-09-17 中国科学院广州生物医药与健康研究院 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
CN107921103A (zh) 2015-08-12 2018-04-17 细胞机械股份有限公司 涉及长半衰期凝血复合物的方法和组合物
GB201520021D0 (en) * 2015-11-13 2015-12-30 Asterion Ltd Fusion polypeptide
NZ744185A (en) 2015-12-30 2025-09-26 Kodiak Sciences Inc Antibodies and conjugates thereof
US11098133B2 (en) 2016-05-19 2021-08-24 President And Fellows Of Harvard College Methods of making gels and films using curli nanofibers
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技(上海)有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技(上海)有限公司 用于构建融合蛋白的连接肽
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技(上海)有限公司 双特异性抗体及其制备方法与用途
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
CN108623695B (zh) * 2017-03-24 2022-03-15 中国科学院过程工程研究所 一种白蛋白结合肽-人睫状神经营养因子融合蛋白及其制备方法和应用
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
GB201706781D0 (en) 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US12440572B2 (en) * 2018-05-18 2025-10-14 Zhengzhou Gensciences Inc. FVIII fusion protein and use thereof
WO2019219048A1 (zh) * 2018-05-18 2019-11-21 北京辅仁瑞辉生物医药研究院有限公司 具有延长半衰期的融合多肽缀合物
DK3793588T3 (da) 2018-05-18 2025-06-16 Bioverativ Therapeutics Inc Fremgangsmåder til behandling af hæmofili a
CN110950964B (zh) * 2018-09-26 2021-06-18 安源医药科技(上海)有限公司 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
AU2020342349A1 (en) * 2019-09-02 2022-03-03 Biotest Ag Factor VIII protein with increased half-life
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
KR20220130692A (ko) * 2020-01-20 2022-09-27 우시 바이올로직스 아일랜드 리미티드 친화성 크로마토그래피를 위한 신규한 세척 완충제 용액
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
JP2023542389A (ja) * 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー 自己抗体で媒介される状態の予防又は治療のための化合物
TWI878902B (zh) * 2022-05-25 2025-04-01 大陸商江蘇晟斯生物製藥有限公司 具有延長的半衰期的fviii融合蛋白綴合物及其應用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009343A1 (fr) 1987-05-29 1988-12-01 Sagami Chemical Research Center Proteine fusionnee contenant une lymphotoxine
AU2645588A (en) 1987-12-04 1989-06-15 Scripps Clinic And Research Foundation The von willebrand factor binding domain of factor viii
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US6939677B1 (en) 1990-11-01 2005-09-06 Cancer Research Fund Of Contra Costa Antibody with 46 kdalton HMFG antigen binding specificity, immunoassay kit and diagnostic method
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6524572B1 (en) 2000-06-26 2003-02-25 Rainbow Therapeutic Company Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
EP2305311A3 (en) 2001-10-10 2011-07-20 BioGeneriX AG Glycoconjugation of peptides
EP2272533A1 (en) 2003-01-13 2011-01-12 MacroGenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
WO2005040382A2 (de) 2003-10-28 2005-05-06 Alexander Cherkasky Cherkasky - fusionsproteine enthaltend antikorperbinde-, antigenbinde - mikrotubulibinde und immunantwortauslosende
WO2005113584A1 (en) 2004-04-29 2005-12-01 Board Of Regents, University Of Texas System Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting
ATE527371T1 (de) 2005-03-24 2011-10-15 Biogenerix Ag Expression löslicher, aktiver, eukaryotischer glucosyltransferasen in prokaryotischen organismen
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
WO2007065691A2 (en) 2005-12-07 2007-06-14 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
EP1980615A4 (en) 2006-01-31 2010-04-21 Ishihara Sangyo Kaisha POLYPEPTIDE WITH AFFINITY FOR A CURVED VIRUS COMPONENT AND USE THEREOF IN THE TRANSFER OF A SUBSTANCE INTO A CELL
ES2531934T3 (es) * 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
AU2007338298B2 (en) * 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
AU2008209436A1 (en) * 2007-01-23 2008-07-31 Zymogenetics, Inc. Soluble Fc gamma R1a for reducing inflammation
US8043621B2 (en) 2007-05-10 2011-10-25 Ramot At Tel Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
JP5314033B2 (ja) * 2007-10-22 2013-10-16 メルク セローノ ソシエテ アノニム 突然変異IgGFcフラグメントと融合した単一IFN−ベータ
CN101965200B (zh) * 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 缀合的因子ⅷ分子
AU2009262476C1 (en) * 2008-06-24 2016-06-02 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life

Similar Documents

Publication Publication Date Title
JP2013519699A5 (enExample)
JP6559642B2 (ja) Fviiiの特定部位の変更
JP6527918B2 (ja) 第viii因子組成物、ならびに組成物の作製方法および用途
TWI686404B (zh) 重組因子viii蛋白
JP2018104459A (ja) 血友病の治療に適する化合物
JP2017503509A5 (enExample)
JP2019531087A (ja) 高グリコシル化ヒト血液凝固第viii因子の融合タンパク質、その調製方法、および使用
JP2015527882A5 (enExample)
JP6605593B2 (ja) 第viii因子およびフォン・ヴィルブランド因子ペプチドを含む製剤
JP2010202664A (ja) 第viii因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト
JP2016522219A (ja) 血友病の治療に適する化合物
JP2015519313A (ja) 血友病の治療に適する医薬組成物
JP2025121974A (ja) Siglec依存的免疫応答をモジュレートするポリペプチド
WO2020063562A1 (zh) 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
WO2017050820A1 (en) Fviii fusion proteins
KR20250168493A (ko) 개선된 약동학을 갖는 fviii-vwf 융합 단백질